SCHEMBL15033607

SCHEMBL15033607

Cc1ccc(CSCCNC(=O)c2ccccc2Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.68
ALDH1A1 P00352 8/20 0.65
HPGD P15428 6/20 0.63
ALOX12 P18054 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
POLB P06746 2/20 0.56
PKM P14618 2/20 0.55
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 2/20 0.54
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15033592 0.86 HPGD (0.53) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15033598 0.86 ALDH1A1 (0.61) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15033610 0.86 ALDH1A1 (0.67) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15033594 0.85 ALDH1A1 (0.62) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15033596 0.81 ALDH1A1 (0.67) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15033608 0.81 ALDH1A1 (0.60) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15686093 0.79 HPGD (0.68) LMNAALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL18775352 0.76 ALDH1A1 (0.68) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL14702014 0.76 ALDH1A1 (0.72) LMNAALDH1A1HPGDALOX12SMN1; SMN2
SCHEMBL15023481 0.76 LMNA (0.67) LMNAALDH1A1HPGDALOX12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158112-A1 COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION CASE WESTERN RESERVE UNIVERSITY 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158112-A1 COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION IAPP, APP, BACE1 LMNA 737/4885ALDH1A1 4152/4885HPGD 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.